Are China Hospital Purchases Slowing? Ask Mindray
This article was originally published in PharmAsia News
China’s largest medical device maker surprised everyone by posting overall second-quarter net revenue growth of 9% to $334.5 million amid challenging market conditions. It expects a further recovery in the second half, but conditions at home remain difficult.
You may also be interested in...
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.